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Introduction
This training grant is a Postdoctoral Fellowship Award in breast cancer research. The project involves focused mentorship and training in breast cancer research, with a particular focus on molecular epidemiology of breast cancer. During the previous year, the PI performed several research activities that further developed necessary skills and knowledge to independently carry out innovative multi-disciplinary breast cancer research. These include 1) quantitative assessment of bioassays in epidemiologic research setting; 2) incorporation of breast cancer biology in epidemiologic data analyses; and 3) development of new research projects.
The research segment of this grant is leading a case-cohort study within the Sister Study, a large prospective cohort study of women with family history of breast cancer, to investigate the major determinants of urinary prostaglandin E 2 -metabolite (PGE-M) and how the urinary level of PGE-M interacts with estrogen biosynthesis in relation to breast cancer risk in postmenopausal women. At the beginning of the project, the PI experienced administrative delay in obligating and transferring funds to a contract laboratory. Moreover, the PI and her mentor decided to switch to a novel method for estrogen quantification because of scientific merit and sample efficiency (justified in the 2010 Annual Summary). Despite those unexpected events, the proposed project has made significant progresses during the last year, and the PI has learned valuable lessons on how to achieve the best possible results in unplanned circumstances.
Body
The objective of the proposed study was to determine how urinary levels of PGE-M interact with estrogen biosynthesis and influences breast cancer risk in postmenopausal women. A case-cohort analysis nested in a large national cohort of women was composed of 607 postmenopausal women who were aged 50 years or older and did not report current use of hormones, including 310 incident breast cancer cases (246 estrogen receptor [ER] positive; 40 ER negative, and 24 unknown ER status). Levels of PGE-M and estrogen metabolites were or are being quantified using novel liquid chromatography/tandem mass spectrometry techniques; therefore, additional quality control experiments were conducted using internal funds to ensure sufficient levels of assay performance to address the proposed study aims.
As of January 2012, all planned PGE-M analysis was completed. As described in the Request for an Extension without Funds (EWOF), however, estrogen analysis is still in progress, and is expected to be complete by the end of April 2012. Hence, this present Annual Report summarizes results from the quality control experiments of PGE-M and estrogen metabolites, and preliminary results of PGE-M analysis. Briefly, within-and betweenbatch % coefficients of variations (%CV) for PGE-M were 8% and 19%, which are within the acceptable range (Table 1) .
A short-term reliability of PGE-M measurements was also estimated using 100 samples from 12 individuals who provided urine samples at three time points across 9 months. After controlling for batch effect, 64% of the total variance in PGE-M measurements was attributed to between-subject variability (Table 2) . However, the short-term reliability was reduced to approximately 42% for creatinine-adjusted PGE-M measurements, regardless of adjustment for batch effect.
Out of 607 study samples for the case-cohort analysis, PGE-M levels were obtained in 604 women with geometric mean of 5.4 ng/mg Cr. (95% CI: 5.1-5.7). Signal for PGE-M was not detected in 3 subjects even after reanalysis. One of the proposed study aims was to identify factors affecting urinary levels of PGE-M in postmenopausal women. In our preliminary analysis, obesity, current smoking and history of diabetes and cardiovascular diseases were independently associated with higher levels of PGE-M (all p-values < 0.05, except for history of cardiovascular diseases with p=0.08) [ Table 3 ]. On the other hand, women with rheumatoid arthritis had lower levels of PGE-M compared to those who didn't report having the condition (adjusted mean PGE-M: 5.5 vs. 4.4; p=0.06), which is postulated to be related to long-term use of nonsteroidal antiinflammatory drugs. Age was not associated with PGE-M levels.
As for estrogen analyses, the results of the recently-completed quality control experiments are promising, yielding excellent %CVs (2.7% for parent estrogens; 5.9% of C2-hydroxylated estrogen metabolites [EMs], 7.1% for C4-hydroxylated EMs, 15.4% for C4-methlated EMs; and 8.4% for C16-hydroxiylated EMs)[ Table  4b ]. Statistical analyses to address the study aims as well as laboratory analysis of estrogens in the case-cohort sample are currently ongoing. It is expected that the present study will achieve the objectives of the study, contributing to understanding the role of inflammation in estrogen biosynthesis and breast cancer risk in postmenopausal women.
Key Research Accomplishments
Progress in proposed research project  Prior to the analysis of study samples for PGE-M, additional quality control experiments were conducted using 100 samples from 12 women who provided urine samples at three different time points over 9 months. Samples were arranged across 5 batches to assess not only the reliability of the assay but also a short-term reproducibility of PGE-M measurement within individuals over time.

Laboratory analyses of 607 study samples for PGE-M and creatinine were completed in November 2011. However, selected batches of samples showed relatively poor reproducibility. We believe this was due to equipment maintenance issues that were subsequently resolved. Reanalysis of affected batches (along with samples from earlier batches for quality control purposes) has been also recently completed with satisfactory results.
For estrogen analysis, we have collaborated with the only NCI-licensed laboratory to ensure adequate levels of sensitivity and reliability of the assays. A series of quality control experiments followed by regular conference calls between the NIEHS investigators and chemists at the contract laboratory were conducted to detect source of technical errors. The second QC experiment results became available the first week of January 2012, showing sufficiently high sensitivity and reliability to move forward to analyze our study samples. Other breast cancer research projects  Reported that telomere length in peripheral blood was not associated with breast cancer risk in the prospective Sister Study cohort.  Published a research paper that examined the reliability of telomere length measurements using sequential samples collected over a 9-month period. This manuscript reported good short-term reliability of telomere length measurements using blood from a single blood draw. However, the existence of technical variability, particularly batch effect, reinforces the need for technical replicates and balancing of case and control samples across plates.
Readied two manuscripts for submission. The first manuscript about genetic variants in DNA and histone methylation and telomere length has been submitted for publication. A manuscript on microsatellite instability in relation to survival of African American and white patients with colorectal cancer, which was a collaborative project with Drs. Keku and Sandler at UNC, has also been submitted. address the study questions. The PI has also accumulated knowledge on breast cancer biology through various venues and has incorporated new ideas into the analyses of epidemiologic data, aiming to give new perspectives to old questions. These efforts should provide good preparation for a new position at an academic institution. The laboratory analysis of estrogens is scheduled to complete by the end of April, 2012. In the next five months, the PI will conduct a full analysis to investigate the interrelationships between PGE-M, estrogens and postmenopausal breast cancer risk, in accordance with the approved Statement of Work for this grant. 15.2 C4-hydroxylated (4-OHE1, 4-MeOE1, 4-MeOE2) 7.1 C2-hydroxylated only (2-OHE1, 2-OHE2) 5.3 C2-methylated only (2-MeOE1, 2-MeOE2) 9.7 C2-hydroxylated (2-OHE1, 2-OHE2, 3-MeOE1, 2-MeOE1, 2-MeOE2) 5.9 C16-hydroxylated 8.4 Total EMs 5.8 1 Based on 3 pairs of 4 replicate samples and 3 pairs of duplicate samples (21 samples)
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